[Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].
The multi-center non-randomized clinical study included 38 patients, aged 31-70, with morphologically (histologically and/or cytologically) verified diagnosis of disseminated cutaneous melanoma established objective response in 18.5% and clinically significant effect (55.5%) following first-line treatment with fotemustine in conjunction with cisplatin and tamoxifen. Fotemustine as a first-line component of combination chemotherapy retarded metastatic spread to the brain. Since side-effects incidence was not high, the regimen may be used under outpatient hospital conditions.
Konstantinova
M M
MM
Gershanovich
M L
ML
Akimov
M A
MA
Nosov
D A
DA
Bogdanova
N V
NV
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000517:prevention & control* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D009943:Organophosphorus Compounds / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome
D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D013629:Tamoxifen; C054368:fotemustine; D002945:Cisplatin